Objective： The aim of our study was to evaluate the efficacy and safety of gemcitabine and cisplatin in patients with previously untreated advanced malignant pleural mesothelioma （MPM）. Methods： Thirty-three eligi...Objective： The aim of our study was to evaluate the efficacy and safety of gemcitabine and cisplatin in patients with previously untreated advanced malignant pleural mesothelioma （MPM）. Methods： Thirty-three eligible patients with histologically proven advanced MPM with ECOG PS of 〈 2 and had adequate liver and kidney functions received gemcitabine （1000 mg/m2） on days 1 and 8 combined with cisplatin （80 mg/m^2） on day 1. Results： The majority of the study group were males and constituted 87.9% （n = 29）, while females constituted 12.1% （n = 4）. The median age was 52 years and ranged from 37 to 69 years. Regarding SWOG performance status, 5 patients were PS 0, 21 patients were PS 1 and 7 patients were PS 2. Regarding pathological subtypes, epithelial histology represented 84.8% of the study （n = 28） while sarcomatoid type represented 6% （n = 2） and biphasic type accounted for 9% （n = 3）. Regarding staging according to IMIG staging system, 12.1% of patients were stage Ⅱ, 54.5% were stage Ⅲand 33.3% were stage Ⅳ. Only one patient （3%） had attained a complete response, 18 patients （54.5%） showed partial response, 12 patients （36.4%） showed stationary disease, while 2 patients （6.1%） showed progressive disease. The correlation between response rate obtained and PS was statistically significant （P = 0.029）. After a median follow-up of 14.4 months, the median survival time was 20.3 months （95% Cl： 14.58-26.01 months） and the progression free survival time was 11.8 months （95% CI： 10.76-12.83 months） Conclusion： The combination of gemcitabine and cisplatin is an active and safe treatment in patients with MPM. Further larger comparative studies are warranted to document this finding.展开更多
文摘Objective： The aim of our study was to evaluate the efficacy and safety of gemcitabine and cisplatin in patients with previously untreated advanced malignant pleural mesothelioma （MPM）. Methods： Thirty-three eligible patients with histologically proven advanced MPM with ECOG PS of 〈 2 and had adequate liver and kidney functions received gemcitabine （1000 mg/m2） on days 1 and 8 combined with cisplatin （80 mg/m^2） on day 1. Results： The majority of the study group were males and constituted 87.9% （n = 29）, while females constituted 12.1% （n = 4）. The median age was 52 years and ranged from 37 to 69 years. Regarding SWOG performance status, 5 patients were PS 0, 21 patients were PS 1 and 7 patients were PS 2. Regarding pathological subtypes, epithelial histology represented 84.8% of the study （n = 28） while sarcomatoid type represented 6% （n = 2） and biphasic type accounted for 9% （n = 3）. Regarding staging according to IMIG staging system, 12.1% of patients were stage Ⅱ, 54.5% were stage Ⅲand 33.3% were stage Ⅳ. Only one patient （3%） had attained a complete response, 18 patients （54.5%） showed partial response, 12 patients （36.4%） showed stationary disease, while 2 patients （6.1%） showed progressive disease. The correlation between response rate obtained and PS was statistically significant （P = 0.029）. After a median follow-up of 14.4 months, the median survival time was 20.3 months （95% Cl： 14.58-26.01 months） and the progression free survival time was 11.8 months （95% CI： 10.76-12.83 months） Conclusion： The combination of gemcitabine and cisplatin is an active and safe treatment in patients with MPM. Further larger comparative studies are warranted to document this finding.
